Berretta M - Search Results

1

Glutathione: Lights and Shadows in Cancer Patients.

Marini HR, Facchini BA, di Francia R, Freni J, Puzzolo D, Montella L, Facchini G, Ottaiano A, Berretta M, Minutoli L. Marini HR, et al. Among authors: berretta m. Biomedicines. 2023 Aug 8;11(8):2226. doi: 10.3390/biomedicines11082226. Biomedicines. 2023. PMID: 37626722 Free PMC article. Review.

2

Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics.

Di Francia R, Frigeri F, Berretta M, Cecchin E, Orlando C, Pinto A, Pinzani P. Di Francia R, et al. Among authors: berretta m. Clin Chem Lab Med. 2010 Apr;48(4):447-59. doi: 10.1515/CCLM.2010.112. Clin Chem Lab Med. 2010. PMID: 20192881 Review.

3

Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.

Di Francia R, Berretta M, Catapano O, Canzoniero LM, Formisano L. Di Francia R, et al. Among authors: berretta m. Clin Chem Lab Med. 2011 Jul;49(7):1105-11. doi: 10.1515/CCLM.2011.181. Epub 2011 Apr 20. Clin Chem Lab Med. 2011. PMID: 21504372 Review.

4

Genetic variants influencing fluoropyrimidine based-therapy and available methods to detect them.

Di Francia R, Cimino L, Berretta M. Di Francia R, et al. Among authors: berretta m. Eur Rev Med Pharmacol Sci. 2012 Mar;16(3):285-98. Eur Rev Med Pharmacol Sci. 2012. PMID: 22530343 Review.

5

Knowledge and skills needs for health professions about pharmacogenomics testing field.

Di Francia R, Valente D, Catapano O, Rupolo M, Tirelli U, Berretta M. Di Francia R, et al. Among authors: berretta m. Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):781-8. Eur Rev Med Pharmacol Sci. 2012. PMID: 22913211 Review.

6

Pharmacogenomics panel test for prevention toxicity in patient who receive Fluoropirimidine/Oxaliplatin-based therapy.

Di Francia R, Siesto RS, Valente D, Spart D, Berretta M. Di Francia R, et al. Among authors: berretta m. Eur Rev Med Pharmacol Sci. 2012 Sep;16(9):1211-7. Eur Rev Med Pharmacol Sci. 2012. PMID: 23047504 Free article. Review.

7

Intravesical chemo-immunotherapy in non muscle invasive bladder cancer.

Leopardo D, Cecere SC, Di Napoli M, Cavaliere C, Pisano C, Striano S, Marra L, Menna L, Claudio L, Perdonà S, Setola S, Berretta M, Franco R, Tambaro R, Pignata S, Facchini G. Leopardo D, et al. Among authors: berretta m. Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2145-58. Eur Rev Med Pharmacol Sci. 2013. PMID: 23893180 Free article. Review.

8

Prognostic value of PUMA expression in patients with HBV-related hepatocellular carcinoma.

Berretta M, Di Francia R, Martella L, Tirelli U. Berretta M, et al. Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1117-8. Eur Rev Med Pharmacol Sci. 2015. PMID: 25912566 Free article. No abstract available.

9

Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.

Berretta M, Di Francia R, Tirelli U. Berretta M, et al. Eur Rev Med Pharmacol Sci. 2015;19(14):2521-2. Eur Rev Med Pharmacol Sci. 2015. PMID: 26221876 Free article. No abstract available.

10

Effect of anti-oxidant agents in patients with hepatocellular diseases.

Di Francia R, Rinaldi L, Troisi A, Di Benedetto F, Berretta M. Di Francia R, et al. Among authors: berretta m. Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):3993-5. Eur Rev Med Pharmacol Sci. 2015. PMID: 26592818 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

404 results

Search Page